Patents by Inventor Martin Clive Hutchings

Martin Clive Hutchings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused pentacyclic imidazole derivatives
    Patent number: 11912721
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 27, 2024
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS
    Publication number: 20230271951
    Abstract: A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: April 6, 2021
    Publication date: August 31, 2023
    Inventors: Prafulkumar Tulshibhai CHOVATIA, Anne Marie FOLEY, Gregory William HASLETT, Martin Clive HUTCHINGS, James Andrew JOHNSON, Fabien Claude LECOMTE, Nathaniel Julius Thomas MONCK, Joanna Rachel QUINCEY, Konstantinos RAMPALAKOS, James Thomas REUBERSON, Adam Peter SMALLEY, Giancarlo TRANI, Darshan Gunvant VAIDYA
  • Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
    Publication number: 20230250105
    Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: February 27, 2023
    Publication date: August 10, 2023
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
    Publication number: 20210252012
    Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: February 15, 2021
    Publication date: August 19, 2021
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Fused Pentacyclic Imidazole Derivatives
    Publication number: 20210155637
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 27, 2021
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Fused pentacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10980814
    Abstract: Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R1, R2, and R3 are defined herein. These compounds are potent modulators of human TNF? activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 20, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Fused pentacyclic imidazole derivatives
    Patent number: 10906919
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 2, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
    Publication number: 20200046723
    Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: February 13, 2020
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Fused Pentacyclic Imidazole Derivatives
    Publication number: 20190367535
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 5, 2019
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Fused pentacyclic imidazole derivatives
    Patent number: 10202405
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 12, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Indazole Derivatives as Modulators of TNF Activity
    Publication number: 20180222868
    Abstract: A series of substituted indazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 7, 2016
    Publication date: August 9, 2018
    Inventors: Prafulkumar Tulshibhai Chovatia, Martin Clive Hutchings, Boris Kroeplien, James Thomas Reuberson
  • Imidazopyridazine derivatives as modulators of TNF activity
    Patent number: 9873703
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 23, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter, Joanna Rachel Quincey
  • Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
    Patent number: 9815797
    Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: November 14, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Rikki Peter Alexander, Gregory Foulkes, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, James Thomas Reuberson, Sarah Margaret Rook, Zhaoning Zhu
  • Fused Pentacyclic Imidazole Derivatives
    Publication number: 20170305932
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • TNF -? modulating benzimidazoles
    Patent number: 9550737
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: January 24, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley
  • Imidazopyridazine Derivatives as Modulators of TNF Activity
    Publication number: 20160376275
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Mezher Hussein ALI, Daniel Christopher BROOKINGS, Julien Alistair BROWN, Martin Clive HUTCHINGS, Victoria Elizabeth JACKSON, Boris KROEPLIEN, John Robert PORTER, Joanna Rachel QUINCEY
  • Fused Bicyclic Heteroaromatic Derivatives As Modulators of TNF Activity
    Publication number: 20160304470
    Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Rikki Peter Alexander, Gregory Foulkes, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, James Thomas Reuberson, Sarah Margaret Rook, Zhaoning Zhu
  • Imidazopyridine derivatives as modulators of TNF activity
    Patent number: 9309243
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 12, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Imidazopyridine Derivatives as Modulators of TNF Activity
    Publication number: 20150203486
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 23, 2015
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • TNF -Alpha Modulating Benzimidazoles
    Publication number: 20150152065
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 11, 2013
    Publication date: June 4, 2015
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley